Clene Receives FDA Green Light for CNM-Au8 Accelerated Approval Pathway in ALS Treatment

Key Takeaways

• FDA confirmed CNM-Au8 data may support accelerated approval submission for ALS treatment based on neurofilament light biomarker
• FDA acknowledged neurofilament light could serve as a reasonably likely surrogate endpoint for ALS drug approval
• Clene plans to submit New Drug Application (NDA) for CNM-Au8 in third quarter 2026

---

Clene Inc. has received positive feedback from the FDA regarding its investigational ALS treatment CNM-Au8, clearing the path for an accelerated approval submission based on biomarker data rather than traditional clinical endpoints.

During a recent FDA meeting, regulators stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8. The approval pathway centers on neurofilament light (NfL) biomarker data, which the FDA acknowledged could potentially serve as a reasonably likely surrogate endpoint for ALS treatment efficacy.

Significance for ALS Treatment Landscape

This regulatory milestone represents a significant advancement in ALS drug development, where traditional clinical trials face challenges due to the disease’s rapid progression and limited treatment options. The FDA’s acceptance of NfL as a potential surrogate endpoint could accelerate the approval timeline for CNM-Au8 and establish precedent for future ALS therapies.

CNM-Au8 is Clene’s proprietary nanocatalytic therapy designed to enhance cellular energy metabolism in neurons. The treatment aims to slow disease progression in ALS patients by supporting mitochondrial function and reducing neuroinflammation.

Timeline and Next Steps

Clene expects to submit its NDA for CNM-Au8 to the FDA in the third quarter of 2026. The accelerated approval pathway could potentially bring the treatment to market faster than traditional approval routes, which typically require demonstration of clinical benefit through functional endpoints.

The company’s approach leverages biomarker-driven drug development, reflecting the FDA’s increasing acceptance of surrogate endpoints in rare diseases where conducting large, long-term studies presents significant challenges. If approved, CNM-Au8 would join a limited arsenal of ALS treatments currently available to patients.

---

Frequently Asked Questions

What does accelerated approval mean for ALS patients?

Accelerated approval allows CNM-Au8 to potentially reach patients faster by using biomarker data instead of waiting for traditional clinical outcome measures, though confirmatory studies would still be required post-approval.

When will CNM-Au8 be available to patients?

Clene plans to submit the NDA in Q3 2026, with potential approval and market availability depending on FDA review timelines, likely in 2027 or later if approved.

How does CNM-Au8 compare to existing ALS treatments?

CNM-Au8 represents a novel nanocatalytic approach targeting cellular energy metabolism, potentially offering a different mechanism of action compared to current ALS drugs like riluzole and edaravone.